UK markets close in 41 minutes

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.17-0.05 (-0.53%)
As of 10:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.22
Bid10.20 x 800
Ask10.32 x 800
Day's range10.06 - 10.31
52-week range1.99 - 43.50
Avg. volume1,466,666
Market cap95.812M
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)-21.73
Earnings date09 Nov 2022 - 14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.00
  • Motley Fool

    TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript

    Good morning, everyone, and thank you for joining today to discuss our second quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing its second quarter 2022 financial results. The press release and accompanying presentation are available on the company's website TherapeuticsMD in the investors and media section.

  • Zacks

    TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    TherapeuticsMD Announces Second Quarter 2022 Financial Results

    BOCA RATON, Fla., August 15, 2022--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.